Peficitinib

An overview of the drug Peficitinib

Peficitinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Peficitinib is a Janus kinase inhibitor (JAK inhibitor) used in the treatment of rheumatoid arthritis. It is a small molecule that selectively inhibits the activity of Janus kinases, which are enzymes involved in the signaling pathways of various cytokines and growth factors.

Mechanism of Action

Peficitinib works by inhibiting the activity of Janus kinases, which are crucial for the signaling of several cytokines involved in the inflammatory process. By blocking these pathways, peficitinib reduces inflammation and the immune response, which are central to the pathophysiology of rheumatoid arthritis.

Pharmacokinetics

Peficitinib is administered orally and is absorbed into the bloodstream, where it exerts its effects on the immune system. The drug undergoes metabolism in the liver and is excreted primarily through the kidneys.

Clinical Use

Peficitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is often used in combination with other therapies to achieve better control of the disease.

Side Effects

Common side effects of peficitinib include headache, nausea, and upper respiratory tract infections. More serious side effects can include increased risk of infections, liver enzyme abnormalities, and hematological changes such as anemia and neutropenia.

Development and Approval

Peficitinib was developed as part of ongoing research into JAK inhibitors for the treatment of autoimmune diseases. It has been approved for use in several countries and is undergoing further studies to evaluate its efficacy and safety in other conditions.

Related pages

• Rheumatoid arthritis
• Janus kinase inhibitor
• Cytokine

• 
  Peficitinib